Filtered By:
Source: Annals of Internal Medicine
Condition: SARS
This page shows you your search results in order of date.
Order by Relevance | Date
Total 40 results found since Jan 2013.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
CONCLUSION: Amubarvimab plus romlusevimab was safe and significantly reduced the risk for hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease.PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases of the National Institutes of Health.PMID:37068272 | DOI:10.7326/M22-3428
Source: Annals of Internal Medicine - April 17, 2023 Category: Internal Medicine Authors: Teresa H Evering Kara W Chew Mark J Giganti Carlee Moser Mauricio Pinilla David Alain Wohl Judith S Currier Joseph J Eron Arzhang Cyrus Javan Rachel Bender Ignacio David Margolis Qing Zhu Ji Ma Lijie Zhong Li Yan Ulises D'Andrea Nores Keila Hoover Bharat Source Type: research
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
CONCLUSION: Symptom or viral relapse in the absence of antiviral treatment is common, but the combination of symptom and viral rebound is rare.PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.PMID:36802755 | DOI:10.7326/M22-2381
Source: Annals of Internal Medicine - February 21, 2023 Category: Internal Medicine Authors: Rinki Deo Manish C Choudhary Carlee Moser Justin Ritz Eric S Daar David A Wohl Alexander L Greninger Joseph J Eron Judith S Currier Michael D Hughes Davey M Smith Kara W Chew Jonathan Z Li ACTIV-2/A5401 Study Team † Source Type: research
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
CONCLUSION: Elevated plasma antigen is highly associated with both severity of pulmonary illness and clinically important patient outcomes. Multiple clinical and viral factors are associated with plasma antigen level at presentation. These data support a potential role of ongoing viral replication in the pathogenesis of SARS-CoV-2 in hospitalized patients.PRIMARY FUNDING SOURCE: U.S. government Operation Warp Speed and National Institute of Allergy and Infectious Diseases.PMID:36037469 | DOI:10.7326/M22-0924
Source: Annals of Internal Medicine - August 29, 2022 Category: Internal Medicine Authors: ACTIV-3/TICO Study Group* Source Type: research
